The peak in IL-6 levels after the initial decrease does not suggest COVID-19 relapse; in fact, this occurrence can be attributed to the recovery of nomral T cells

The patient did not exhibit typical symptoms of COVID-19 such as fever and cough but experienced chest tightness and shortness of breath; this suggests that typical symptoms of COVID-19 are not present in patients with coexisting comorbidities such as multiple myleoma (MM)

The patient's condition slowly recovered after tocilzumub treatment, suggesting that tocilizumab is an effective treatment of COVID-19

IL-6 signaling plays a key role in the pathogenesis of MM and thus small molecule inhibitors that target this are extremely effective at stopping MM cell growth; the investigators believe that tocilizumab might also prove to be a useful therapeutic for MM

Overall, this study is the first to report that tocilizumab is an effective treatment for COVID-19 patients also diagnosed with MM